Archives of otolaryngology--head & neck surgery · 2011
Adjuvant radiation therapy for high-grade and/or locally advanced major salivary gland tumors.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mahmood Usama, Koshy Matthew, Goloubeva Olga, Suntharalingam Mohan
Аннотация
OBJECTIVE: To examine the effect of adjuvant radiation therapy (RT) on survival of high-grade and/or locally advanced malignant major salivary gland tumors (MMSGT).
PATIENTS: The study population comprised 2170 patients with high-grade (poorly differentiated or undifferentiated) and/or locally advanced MMSGT (T3/4 or N+).
MAIN OUTCOME MEASURES: The Surveillance, Epidemiology, and End Results registry was used to obtained data for all patients 20 years or older who underwent surgery for high-grade and/or locally advanced nonmetastatic MMSGT between 1988 and 2005. Univariate and multivariable regression analyses were performed to identify factors associated with improved survival.
RESULTS: Seventy-two percent of patients received adjuvant RT, while 28% underwent surgery alone. Patients receiving adjuvant RT were younger and had higher T and N categories and grade. Multivariable analysis revealed significantly improved survival with adjuvant RT (HR for mortality, 0.76; 95% CI, 0.65-0.89; P < .001). Other factors associated with improved survival included younger age at diagnosis, less than radical surgery, certain histologic subtypes, lower grade, and lower T and N categories. Subset analyses found significantly improved survival with adjuvant RT among patients with both high-grade and locally advanced disease (P < .001), involvement of the parotid gland (P = .002), or squamous cell carcinoma (P = .004), with a survival benefit seen among patients with adenocarcinoma that did not reach significance (P = .06).
CONCLUSIONS: Adjuvant RT is associated with improved survival for high-grade and/or locally advanced MMSGT based on analysis of this large, population-based database. Further prospective studies are warranted to examine the role of RT in the management of this disease.
PATIENTS: The study population comprised 2170 patients with high-grade (poorly differentiated or undifferentiated) and/or locally advanced MMSGT (T3/4 or N+).
MAIN OUTCOME MEASURES: The Surveillance, Epidemiology, and End Results registry was used to obtained data for all patients 20 years or older who underwent surgery for high-grade and/or locally advanced nonmetastatic MMSGT between 1988 and 2005. Univariate and multivariable regression analyses were performed to identify factors associated with improved survival.
RESULTS: Seventy-two percent of patients received adjuvant RT, while 28% underwent surgery alone. Patients receiving adjuvant RT were younger and had higher T and N categories and grade. Multivariable analysis revealed significantly improved survival with adjuvant RT (HR for mortality, 0.76; 95% CI, 0.65-0.89; P < .001). Other factors associated with improved survival included younger age at diagnosis, less than radical surgery, certain histologic subtypes, lower grade, and lower T and N categories. Subset analyses found significantly improved survival with adjuvant RT among patients with both high-grade and locally advanced disease (P < .001), involvement of the parotid gland (P = .002), or squamous cell carcinoma (P = .004), with a survival benefit seen among patients with adenocarcinoma that did not reach significance (P = .06).
CONCLUSIONS: Adjuvant RT is associated with improved survival for high-grade and/or locally advanced MMSGT based on analysis of this large, population-based database. Further prospective studies are warranted to examine the role of RT in the management of this disease.